A number of academic groups and companies have focused on the production of cell-based tumor vaccines by cytokine gene transfer. This approach allows sustained local production of the cytokine and maintains a high concentration of cytokine in the vicinity of the cells. However, gene transfer presents numerous problems. As a practical, product-oriented alternative to genetic modification, we are producing cytokines that are engineered to automatically attach to tumor cells when added exogenously, ex vivo. The immunomodulatory portion of the molecule is thus positioned on the outer cell surface and concentrated in the vicinity of the surface, increasing its potency. These molecules, which we have dubbed """"""""opsonokines"""""""", attach to cells through interactions with ubiquitous plasma membrane features. In our Phase 1 SBIR study, a prototype opsonokine-based vaccine has demonstrated excellent antitumor activity in mice. We now continue our in vitro and in vivo studies of the prototype molecule. Over 1,000,000 cases of cancer are diagnosed in the U.S. each year. Current treatment approaches are inadequate. This project seeks to deveop a powerful, practical method for stimulating the immune system to fight this prevalent disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44CA106131-02A1
Application #
6997970
Study Section
Special Emphasis Panel (ZRG1-IMM-G (10))
Program Officer
Welch, Anthony R
Project Start
2004-04-01
Project End
2007-06-30
Budget Start
2005-07-15
Budget End
2006-06-30
Support Year
2
Fiscal Year
2005
Total Cost
$434,930
Indirect Cost
Name
Genitrix, LLC
Department
Type
DUNS #
969875491
City
Cambridge
State
MA
Country
United States
Zip Code
02142